NAS:EIDX (USA) Also Trade In: Germany

Eidos Therapeutics Inc $ 122.21 0 (0%)

Volume:
0
Avg Vol (1m):
123,861
Market Cap $:
4.75 Bil
Enterprise Value $:
4.62 Bil
PE Ratio:
0.00
PB Ratio:
38.39
Warning! GuruFocus has detected 1 Severe warning sign with EIDX. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for EIDX (Eidos Therapeutics Inc) from 2018 to Mar 02 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Eidos Therapeutics stock (EIDX) PE ratio as of Mar 02 2021 is 0. More Details

Eidos Therapeutics PE Ratio (TTM) Chart

EMBED

Eidos Therapeutics PE Ratio (TTM) Historical Data

Total 656
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 8
Eidos Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-03-020.0 2020-11-190.0
2021-01-260.0 2020-11-180.0
2021-01-250.0 2020-11-170.0
2021-01-220.0 2020-11-160.0
2021-01-210.0 2020-11-130.0
2021-01-200.0 2020-11-120.0
2021-01-190.0 2020-11-110.0
2021-01-150.0 2020-11-100.0
2021-01-140.0 2020-11-090.0
2021-01-130.0 2020-11-060.0
2021-01-120.0 2020-11-050.0
2021-01-110.0 2020-11-040.0
2021-01-080.0 2020-11-030.0
2021-01-070.0 2020-11-020.0
2021-01-060.0 2020-10-300.0
2021-01-050.0 2020-10-290.0
2021-01-040.0 2020-10-280.0
2020-12-310.0 2020-10-270.0
2020-12-300.0 2020-10-260.0
2020-12-290.0 2020-10-230.0
2020-12-280.0 2020-10-220.0
2020-12-240.0 2020-10-210.0
2020-12-230.0 2020-10-200.0
2020-12-220.0 2020-10-190.0
2020-12-210.0 2020-10-160.0
2020-12-180.0 2020-10-150.0
2020-12-170.0 2020-10-140.0
2020-12-160.0 2020-10-130.0
2020-12-150.0 2020-10-120.0
2020-12-140.0 2020-10-090.0
2020-12-110.0 2020-10-080.0
2020-12-100.0 2020-10-070.0
2020-12-090.0 2020-10-060.0
2020-12-080.0 2020-10-050.0
2020-12-070.0 2020-10-020.0
2020-12-040.0 2020-10-010.0
2020-12-030.0 2020-09-300.0
2020-12-020.0 2020-09-290.0
2020-12-010.0 2020-09-280.0
2020-11-300.0 2020-09-250.0
2020-11-270.0 2020-09-240.0
2020-11-250.0 2020-09-230.0
2020-11-240.0 2020-09-220.0
2020-11-230.0 2020-09-210.0
2020-11-200.0 2020-09-180.0

Eidos Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries 6MX.Germany EIDX.USA
Address 101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.